Generation Bold Radio, June 7, 2020--Guests: Josh Cohen & Justin Klee, Amylyx Pharmaceuticals
Joshua Cohen co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Josh has overseen the growth of Amylyx from a dorm-room concept to a clinical stage pharmaceutical company. His research experience includes work both at Brown University and at the National Institute of Standards in Technology. Josh received his BS in biomedical engineering from Brown University.
Justin Klee, Co-CEO and Co-Founder
Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Along with his co-founder Josh, Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Sc.B in Neuroscience from Brown University.